Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-08-06
DOI
10.3389/fonc.2022.971594
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences
- (2022) Alessandro De Vita et al. Biomedicines
- 3-T magnetic resonance–guided high-intensity focused ultrasound (3 T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors
- (2022) Alberto Bongiovanni et al. SUPPORTIVE CARE IN CANCER
- Percutaneous thermal ablation of sacral metastases: Assessment of pain relief and local tumor control
- (2021) Roberto L. Cazzato et al. Diagnostic and Interventional Imaging
- Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2 ‐negative metastatic breast cancer
- (2021) Hyehyun Jeong et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and safety of JMT103 in patients with giant cell tumor of bone: A multicenter, single-arm, open-label, phase Ib/II study.
- (2021) Xiaohui Niu et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
- (2021) Nathalie Gaspar et al. LANCET ONCOLOGY
- Sex, racial/ethnic and socioeconomic disparities in patients with metastatic bone disease
- (2021) Muhammad Umar Jawad et al. JOURNAL OF SURGICAL ONCOLOGY
- Racial disparities in bone metastasis patterns and targeted screening and treatment strategies in newly diagnosed lung cancer patients
- (2020) Guijun Xu et al. ETHNICITY & HEALTH
- Bone Metastasis: Mechanisms, Therapies and Biomarkers
- (2020) Philippe Clezardin et al. PHYSIOLOGICAL REVIEWS
- Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells
- (2019) Aude I. Segaliny et al. EBioMedicine
- Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma
- (2018) James J. Harding et al. Journal of the National Comprehensive Cancer Network
- Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study
- (2018) Qian Chen et al. PLoS One
- Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update
- (2017) Catherine Van Poznak et al. JOURNAL OF CLINICAL ONCOLOGY
- Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials
- (2017) Andrew S. Gdowski et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Racial variation in the clinical and economic burden of skeletal-related events among elderly men with stage IV metastatic prostate cancer
- (2015) Jinani Jayasekera et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Bone health in cancer patients: ESMO Clinical Practice Guidelines
- (2014) R. Coleman et al. ANNALS OF ONCOLOGY
- The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review
- (2014) Winnie Sohn et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics
- (2014) J. Fang et al. Clinical & Translational Oncology
- Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
- (2012) Noopur Raje et al. Clinical Interventions in Aging
- A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women
- (2011) Yuji Kumagai et al. BONE
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab and bisphosphonates: Different mechanisms of action and effects
- (2010) Roland Baron et al. BONE
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
- (2009) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases
- (2008) Kan Yonemori et al. CANCER SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More